UNSPSC 51273102: Eltanolone

This classification denotes an anesthetic agent with the molecular formula C21H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BXO86P3XXW, chemically known as 5beta-pregnan-20-one, 3alpha-hydroxy- (8ci) but generally known as eltanolone, which bears US NIH Compound Identifier 31402. European Medicines Agency schedules Eltanolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06494MIG. The term ELTANOLONE is an International Non-Proprietary Name.

UNSPSC 51273102 Eltanolone is a Commodity code that does not align with the recent state and local opportunities tagged under it. The three most recent solicitations—a Florida county procurement for naloxone and drug deactivation systems, a Texas HHS Request for Information on direct-to-manufacturer prescriptions, and a Minnesota cooperative purchasing agreement for generic pharmaceuticals and OTC products—address pharmaceutical procurement, drug supply chain, and pharmacy benefit management but do not reference eltanolone, a neurosteroid pharmaceutical compound, as a line item or procurement focus. The opportunities show state and local governments buying naloxone kits, generic pharmaceutical products through authorized wholesale distribution channels, and exploring vendor capabilities for direct manufacturer contracting models, but no recent solicitations specifically target eltanolone procurement.

The code shows little relevant recent activity; the mismatch between the code name and the actual scope of posted opportunities suggests either tagging inconsistency in the source system or that eltanolone procurement does not represent current state and local government buying patterns. Issuing bodies pursuing pharmaceutical procurement—Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration via the MMCAP cooperative—are engaging in broader drug acquisition and supply management rather than eltanolone-specific sourcing. Vendors should verify whether their eltanolone offering aligns with state and local pharmaceutical benefit programs, formulary positions, and therapeutic uses before pursuing these avenues; current posted activity does not support eltanolone as a standalone procurement category at the state and local level.